Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus Vinorelbine in Pretreated HER2+ Metastatic Breast Cancer
NCT01161368Phase 2Terminated
- Sponsor
- Central European Cooperative Oncology Group
- Start
- Sep 2010
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of lapatinib in HER2-positive metastatic breast cancer, sponsored by Central European Cooperative Oncology Group. Started Sep 2010; status: terminated.
02
Drugs
lapatinib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT01161368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01161368.